This product is an active protein and may elicit a biological response in vivo, handle with caution.
Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.2-0.5 mg/ml. This solution can then be diluted into other aqueous buffers and stored at 4oC for 1 week or -20oC for future use. Repeated freeze thaw cycles will result in some loss of activity.
Fibroblast growth factor 9
GAF (Glia-activafibroblast growth factor 9 (glia-activating factor)
Glia Activating Factor
Heparin-binding growth factor 9
May have a role in glial cell growth and differentiation during development, gliosis during repair and regeneration of brain tissue after damage, differentiation and survival of neuronal cells, and growth stimulation of glial tumors.
Involvement in disease
Defects in FGF9 are the cause of multiple synostoses syndrome type 3 (SYNS3) [MIM:612961]. Multiple synostoses syndrome is an autosomal dominant condition characterized by progressive joint fusions of the fingers, wrists, ankles and cervical spine, characteristic facies and progressive conductive deafness.
Belongs to the heparin-binding growth factors family.
Three molecular species were found (30 kDa, 29 kDa and 25 kDa), cleaved at Leu-4, Val-13 and Ser-34 respectively. The smaller ones might be products of proteolytic digestion. Furthermore, there may be a functional signal sequence in the 30 kDa species which is uncleavable in the secretion step. N-glycosylated.